-+ 0.00%
-+ 0.00%
-+ 0.00%
ClearPoint Neuro Q3 net loss widens 27% to $7.46 million; Q3 revenue rises 36% to $12.1 million
Share
Listen to the news
ClearPoint Neuro Q3 net loss widens 27% to $7.46 million; Q3 revenue rises 36% to $12.1 million
  • ClearPoint Neuro’s third-quarter net loss widened 27% to $7.46 million, while revenue rose 36% to $12.1 million year over year.
  • Neurosurgery navigation and therapy revenue climbed 59% to $5.4 million; capital equipment and software revenue jumped 68% to $1.7 million.
  • A partner submitted its first formal BLA for Huntington’s disease treatment.
  • The company now expects 2026 revenue between $48 million and $50 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ClearPoint Neuro Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610281605ACCESSWRNAPR_____1243359) on October 28, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending